A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Trial details
- Registry ID
- NCT04633122
- Phase
- Phase 2
The FDA approved Ripretinib (DCC-2618) on 15 May 2020.
Drug identity checked against registry records
Also recorded as DCC-2618
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With ImatinibNCT04633122 | Zai Lab (Shanghai) Co., Ltd. | Phase 2 | Completed | 2022-07-20Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2020-05-15Day | Ripretinib | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA213973", "applicant_as_listed_by_fda": "DECIPHERA PHARMS", "brand_names": ["QINLOCK"], "active_ingredients": ["RIPRETINIB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20200515", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |